Ocean Biomedical (Ocean Biomedical) Cash Flow from Financing : $10.64 Mil (TTM As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Ocean Biomedical Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2023, Ocean Biomedical paid $51.61 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $51.61 Mil on other financial activities. In all, Ocean Biomedical spent $0.00 Mil on financial activities for the three months ended in Sep. 2023.

Ocean Biomedical Cash Flow from Financing Historical Data

The historical data trend for Ocean Biomedical's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocean Biomedical Cash Flow from Financing Chart

Ocean Biomedical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash Flow from Financing

0.06

1.11

2.10

Ocean Biomedical Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash Flow from Financing	Get a 7-Day Free Trial										0.16	1.08	2.92	6.64	-

Ocean Biomedical Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Ocean Biomedical's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

	Cash Flow from Financing		(A: Dec. 2022 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	2.1	+	0	+	0	+	0
=	2.10

Ocean Biomedical's Cash from Financing for the quarter that ended in Sep. 2023 is:

	Cash Flow from Financing		(Q: Sep. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	-51.606	+	0	+	0	+	0	+	51.606
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.64 Mil.

Ocean Biomedical (NAS:OCEA) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Ocean Biomedical's issuance of stock for the three months ended in Sep. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Ocean Biomedical's repurchase of stock for the three months ended in Sep. 2023 was $-51.61 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Ocean Biomedical's net issuance of debt for the three months ended in Sep. 2023 was $0.00 Mil. Ocean Biomedical received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Ocean Biomedical's net issuance of preferred for the three months ended in Sep. 2023 was $0.00 Mil. Ocean Biomedical paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Ocean Biomedical's cash flow for dividends for the three months ended in Sep. 2023 was $0.00 Mil. Ocean Biomedical received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Ocean Biomedical's other financing for the three months ended in Sep. 2023 was $51.61 Mil. Ocean Biomedical received $51.61 Mil on other financial activities.

Ocean Biomedical Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Ocean Biomedical's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocean Biomedical (Ocean Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

8AW0:Germany

Address

55 Claverick Street, Room 325, Providence, RI, USA, 02903

Website

https://www.oceanbiomedical.com

Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.

Executives

Robert J Sweeney	officer: Chief Accounting Officer	20298 CRAIGEN CIRCLE, SARATOGA CA 95070
M Michelle Berrey	director	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
William F Owens	director	C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010
Inderjote S Kathuria	officer: Chief Strategy Officer	19W060 AVENUE LATOUR, OAK BROOK IL 60523
Gurinder S Kalra	officer: Chief Financial Officer	2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115
Chirinjeev Kathuria	director	C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484
Jerome Ringo	director	1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303
Poseidon Bio, Llc	10 percent owner	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Daniel Behr	officer: EVP, Innov./Acad. P'ships Head	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jack A Elias	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jonathan Kurtis	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Elizabeth Ng	director, officer: Chief Executive Officer	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Martin D Angle	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Aesther Healthcare Sponsor, Llc	10 percent owner	515 MADISON AVE., SUITE 8078, NEW YORK NY 10022
Michael L Peterson	director	17 CANARY COURT, DANVILLE CA 94526